medigraphic.com

2013, Number 1

<< Back Next >>

Rev Hosp Jua Mex 2013; 80 (1)

Biotransformación y efecto del diltiazem en la pared intestinal

Rodríguez-Wong U, Ocharán-Hernández ME, Toscano-Garibay J, Garrido-Acosta O, Anguiano-Robledo L, Cruz-Rico J, Ruiz-Pérez NJ, Sánchez-Navarrete J, Pérez-Cruz E, Montes-Vera MR

Language: Spanish
References: 37
Page: 34-40
PDF size: 340.55 Kb.


ABSTRACT

Diltiazem is a calcium antagonist that inhibits both slow calcium channel activity in vascular smooth muscle and cardiac muscle, as well as the release of calcium stored in the sarcoplasmic reticulum. Although the liver is recognized as the major site responsible for the metabolism of this drug, there is little information regarding the role of other organs in the biotransformation of diltiazem and its metabolites. The presence of cytochrome P-450 and other biotransforming enzymes in many other organs suggests that extrahepatic tissues contribute to the biotransformation of endogenous and exogenous substrates. In vitro studies have demonstrated that the cytochrome P-450 metabolism necessary for diltiazem and metabolites are present not only in the liver but also in organs such as intestine, kidney and lungs.


REFERENCES

  1. Herman P, Rodger SD, Remones G, Theno JP, London DR, Morselli PL. Pharmacokinetics of Diltiazem After Intravenous and Oral Administration. Eur J Clin Pharmacol 1983; 24: 349-52.

  2. Hockerman GH, Dilmac N, Scheurer T, Catterall WA. Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca2+ channels. Mol Pharmacol 2000; 58: 1264-70.

  3. Bers DM, Perez-Reyes E. Ca channels in cardiac myocytes: Structure and function in Ca influx and intracellular Ca release. Cardiovasc Res 1999; 42: 339-60.

  4. Catterall WA. Structure and function of voltage-gated ion channels. Annu Rev Biochem 1995; 64: 493-531.

  5. Lacinová L’, Klugbauer N, Hofmann F. Low voltage activated calcium channels: from genes to function. Gen Physiol Biophys 2000; 19: 121-36.

  6. Nakayama H, Taki M, Striessnig J, Glossmann H, Catterall WA, Kanaoka Y. Identification of 1,4-dihydropyridine binding regions within the a1 subunit of skeletal muscle Ca21 channels by photoaffinity labeling with diazipine. Proc Natl Acad Sci USA 1999; 88: 9203-7.

  7. Striessnig J, Glossmann H, Catterall WA. Identification of a phenylalkylamine binding region within the a1 subunit of skeletal muscle Ca21 channels. Proc Natl Acad Sci USA 1990; 87: 9108-12.

  8. Buckley MT, Grant SM, Goa KL, Mc Tavish D, Sorkin EM. Diltiazem-A reappraisal of its pharmacological properties and therapeutic use. Drugs 1990; 39: 757-806.

  9. Yeung PKF, Mosher SJ, Quilliam MA, Montague TJ. Species comparison of pharmacokinetics and metabolism of dilitiazem in humans, dogs, rabbits and rats. Drug Metab Dispos 1990; 18: 1055-9.

  10. Sugihara J, Sugawara Y, Ando H, Harigaya , Etoh A, Kohno K. Studies on the metabolism of diltiazem in man. J Pharmacobiodyn 1984; 7: 24-32.

  11. Yabana H, Nagao T, Sato M. Cardiovascular effects of the metabolites of diltiazem in dogs. J Cardiovasc Pharmacol 1985; 7: 152-7.

  12. Homsy W, Lefebre M, Caillé G, du Souich P. Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies. Pharmaceutical Research 1995; 12: 609-14.

  13. Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002; 41: 235-53.

  14. Bianchetti G, Ragazzi M, Rondanelli R, Ascanole V, Morselli PL. Bioavailability of diltiazem as a function of the administered dose. Biopharm Drug Dispos 1991; 12: 391-401.

  15. Sutton D, Buttler AM, Nadin L, Murray M. Role of CYP3A4 in human hepatic hepatic N-desmethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997; 282: 294-300.

  16. Lee YH, Lee MH, Shim CK. Pharmakocinetics of diltiazem and deacetyldiltiazem in rats. Int J Pharm 1991; 76: 71-6.

  17. Sigusch H, Henschel L, Kraul H, Merkel U, Hoffmann A. Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie 1994; 49: 675-9.

  18. Chistensen H, Asberg A, Holmboe AB, Berg KJ. Coadministration of grapefruit juice increased systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol 2002; 58: 515-20.

  19. Boyd RA, Chin SK, Don-Pedro O, Verotta D, Sheiner LB, Willliams RL, et al. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther 1989; 46: 408-19.

  20. Tsui BCH, Feng JDZ, Buckley SJ, Yeung PKF. Pharmacokinetic and metabolism of diltiazem in rats following a single intraarterial or single oral dose.

  21. Iwao T, Inoue K, Hayashi Y, Yuasa H, Watanabe J. Absortion and metabolic absortion of diltiazem from the perfused rat small intestine. Drug Metab Pharmacokinetic 2004; 19: 430-7.

  22. Molden E. Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitro. Drug Metabolism Dispos 1999; 28: 107-9.

  23. Bellamy WT. P-glucoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 1996; 36: 161-83.

  24. Tajiri S, Kanamaru T, Yoshida K, Hosoi Y, Konno T, Yada S, Nakagami H. The relationship between the drug concentratios profiles in plasma and the drug doses in the colon. Chem Pharm Bull 2010; 58: 1295-300.

  25. Hillestad B, Sund RB, Buajordet M. Intestinal handling of bisacodyl and picosulphate by everted sacs of the rat jejunum and stripped colon. Acta Pharmacol Toxicol 1982; 51: 388-94.

  26. Fraile LJ, Aramayona JJ, Bregante MA, García MA, Abadía AR. Deacetylation of diltiazem by several rabbit tissues. Pharm Res 1996; 13: 1875-80.

  27. Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfilis C, Thenot JP, Maurel P. Identification of the rabbit an human cytochromes P-450IIIA as the major enzymes involved in the Ndemethylation of diltiazem. Drug Metab Dispos 1990; 18: 711-9.

  28. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 2006; 23: 1675-86.

  29. Kocher HM, Steward M, Leather AJ, Cullen PT. Randomized clinical trial assessing the side-effects of glyceryl trinitrate and diltiazem hydrochloride in the treatment of chronic anal fissure. Br J Surg 2002; 89(4): 413-7.

  30. Sajid MS, Rimple J, Cheek E, Baig MK. The efficacy of diltiazem and glyceryltrinitrate for the medical management of chronic anal fissure: a meta-analysis. Int J Colorectal Dis 2008; 23(1): 1-6.

  31. Silverman R, Benedick PJ, Wasvary HJ. A randomized, prospective. Double-blind, placebo-controlled trial of the effect of a calcium channel bloker ointment on pain after hemorrhoidectomy. Dis Colon Rectum 2005; 48: 1913-6.

  32. Medhi B, Rao RS, Prakash A, Prakash O, Kaman L, Pandhi P. Recent advances in the pharmacotherapy of chronic anal fissure: an update. Asian J Surg 2008; 31(3): 154-63.

  33. Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. Cochrane Database Syst Rev 2012; 15; 2: CD003431.

  34. Staneva-Stoytcheva D, Venkova K. Effects of the calcium antagonist diltiazem, verapamil and nitrendipina on the contractile responses of guinea-pig isolated ileum to electrical stimulation or carbachol. J Pharm Pharmacol 1992; 44: 321-5.

  35. Jonard P, Essamri B. Diltiazem and internal anal sphincter. Lancet 1987; 1: 754.

  36. Carapeti EA, Kamm MA, Phillips RK. Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects. Dis Colon Rectum 2000; 43(10): 1359-62.

  37. Jonas M, Neal KR, Abercrombie JF. A randomized trial of oral vs. topical diltiazem for chronic anal fissures. Dis Colon Rectum 2001; 44: 1074-8.




2020     |     www.medigraphic.com